Cytotoxic and Cell progression effects of Mentha pulegium L extract on selected cancer cell lines

Document Type : Research Paper

Authors

1 Department of Toxicology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3 Department of Toxicology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

10.22034/ijps.2020.44027

Abstract

Mentha pulegium L. is one of the Mentha (Labiatae) species that is grown in many different parts of the earth including northern Iran. The total ethanolic extract of the aerial parts of this plant is used in this work to investigate on the possible cytotoxicity on two different cell lines. Human lung carcinoma cells (A549) and human breast cancer (MCF7), have been used to show the clonogenic count of cells, as well as their cell cycle phases progression pattern after the exposure to the different concentrations of this extract. The cytotoxicity of the total extract of Mentha pulegium L. is 59 ± 1.73 µg/ml for the MCF7, and 48.86 ± 2.5 µg/ml for the A549 cell lines, respectively. Flow cytometry analysis have shown two different adventures for these cell lines after 24 hours exposure to this extract. While the MCF7 cells presented a dose-dependent arrest at the G2/M phase of the cell cycle, the A549 cells are more intended to accumulate in the so-called G0 resting phase after the exposure to this extract. These promising initial results might bring hope for the introduction of a tissue discriminating anticancer agent in future.

Keywords

References

 
[1] Chalchat J.-C, Gorunovic M.S, Maksimovic Z.A, Petrovic S.D. Essential Oil of Wild Growing Mentha pulegium L. from Yugoslavia. J. Essent. Oil Res. (2000) 12: 598-600.
[2] Aghel N, Yamin A, Hadjiakhoondi A, Pourmortazavi S.M. Supercritical carbon dioxide extraction of Mentha pulegium L. Essential Oil. Talanta. (2004) 62: 407-411.
[3] Chen L.J, Lebetkin E.H, Burka L.T. Metabolism of (R)-(+)-pulegone in F344 rats. Drug. Metab. Dispos. (2001) 29: 1567-1577.
[4] Nidhal S, Bachrouch O, Sriti J, Msaada K, Khammassi S, Hammami M, Selmi S, Boushih E, Koorani S, Abderraba M, Marzouk B, Limam F, Ben Jemaa J.M. Fumigant and repellent potentials of Ricinus communis and Mentha pulegium essential oils against Tribolium castaneum and Lasioderma serricorne. Int. J. Food Prop. (2017) 20:2899-2913.
[5] Samouh Y, Lemrani A, Mimouni H, Mohamad J, Ait Haj Said A. Ethnopharmacological Study of Herbal Medicines used to treat Cancer in Morocco. Phytopharmacology. (2012) 2: 243-256.
[6] Angerhofer C.K, Handbook of Medicinal Herbs. 2nd ed. J. Nat. Prod. (2001) 307-308.
[7] Nikounezhad N, Shirazi F.H, Kamalinejad M, Relative Cytotoxicity of Fractionated Extract of Arial Parts of Mentha Pulegium on Three Cancer Cell Lines. Am. j. PharmTech Res. (2014) 4: 215-223
[8] Naeem M, Hayat M, Qamar S.A, Mehmood F. Risk factors, genetic mutations and prevention of breast cancer. Int. J. Nat. Sci. (2019) 14: 492-496.
[9] Sripan P, H, Sriplung H, Chitapanarux I. Trends in Female Breast Cancer by Age Group in the Chiang Mai Population. Asian Pac. J. Cancer P. (2020) 180: 481-490.
 [10] Moo T-A, Sanford R, Dang C, Morrow M. Overview of Breast Cancer Therapy. PET. Clin. (2018) 13: 339-354.
[11] Geyer C-E, Forster J, Lindquist D, Chan S, Romieu G, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. N. Engl. J. Med. (2006) 355: 2733-2743.
[12] Rahal Z, El Nemr S, Sinjab A, Chami H, Tfayli A, Kadara H. Smoking and Lung Cancer: A Geo-Regional Perspective. Front Oncol. (2017) 7: 1-7.
[13] Tindle H.A, Duncan M.S, Greevy R.A, Vasan R.S, Kundu S, Massion P.P, Freiberg M.S. Lifetime Smoking History and Risk of Lung Cancer: Results From the Framingham Heart Study. J. Natl. Cancer I. (2018) 110: 1201-1207.
[14] Hubaux R, Becker-Santos D.D, Enfield K.SS, Lam S, Lam  W.L,Martinez V.D. Arsenic, asbestos and radon: emerging players in lung tumorigenesis. J. Environ. Health. (2012) 11: 89.
[15] Kanwal A, Ding X.J, Cao Y. Familial risk for lung cancer. Oncol. Lett. 13: 535- 542.
[16] Kim E.S, Chemotherapy Resistance in Lung Cancer. Springer Publishers. (2015) 189-209.
[17] Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A,  Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet. (2019) 20: 625-635.
[18] Ramalingam S.S, Yang J, Lee C.K, Kurata T, Kim D.W, John T, Nogami N, Ohe Y, Mann H,  Rukazenkov Y, Ghiorghiu S, Stetson D,  Markovets A, Barrett J.C, Thress K.S, Jänne P.A. Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol. (2018) 36: 841-849.
[19] Trusheva B, Trunkova D, Bankova V. Different extraction methods of biologically active components from propolis: a preliminary study. BMC Chem. (2007) 1:13.
[20] Franken N.A.P, Rodermond M.H, Stap J,  Haveman J, Bree C.V. Clonogenic assay of cells in vitro. Nat. Protoc. (2006) 1: 2315-2319.
[21] Zaidman B.Z, Wasser P.S, Nevo E, Mahajna J. Androgen receptor-dependent and -independent mechanisms mediate Ganoderma lucidum activities in LNCaP prostate cancer cells. Int. J. Oncol. (2007) 31: 959-967.
[22] Subik K, Lee J.F, Baxter L, Strzepek T,  Costello D, Crowle P, Xing L, Hung M-C, Bonfiglio T, Hicks D.G, Tang P. The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (2010) 4: 35-41.
[23] Xie M, You S, Chen Q, Chen X, Hu C. Progesterone inhibits the migration and invasion of A549 lung cancer cells through membrane progesterone receptor α-mediated mechanisms. Oncol. Rep. (2013) 29: 1873-1880.
[24] Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, Barton C, Ghahramani P, Hirsh V. Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann. Oncol. (2000) 1: 56.
[25] Chi F, Wu R, Jin X, Jiang M, Zhu X. HER2 induces cell proliferation and invasion of non-small-cell lung cancer by upregulating COX-2 expression via MEK/ERK signaling pathway. Onco. Targets Ther. (2016) 9: 2709-2716.
 [26] Goud K.I, Dayakar S,Vijayalaxmi K,  Jangu Babu S, Vijay A.R.P. Evaluation of HER-2/neu status in breast cancer specimens using immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay. Indian J. Med. Sci. (1999) 14: 663-734.
Iranian Journal of Pharmaceutical Sciences
Volume 16, Issue 2
April 2020
Pages 27-34

Files

Share

How to cite

Statistics